Key result
Flecainide prevented catecholamine-induced sustained ventricular tachycardia in RyR2 R4496C+/− mice by increasing the threshold for triggered activity (P < 0.01).
Why the study?
Does flecainide prevent arrhythmias in a mouse model of CPVT by increasing the threshold for triggered activity?
Does flecainide prevent arrhythmias in a mouse model of CPVT by increasing the threshold for triggered activity?
Flecainide exerts its antiarrhythmic effect in CPVT by reducing sodium channel availability and increasing the threshold for triggered activity, rather than by directly altering intracellular calcium homeostasis.
No takes yet. Share an insight, caveat, or question.
Supports Na-channel mechanism in CPVT mouse model; challenges direct RyR2 effects and leaves open human translation.
Liu et al. (2011) studied this question. Flecainide prevented catecholamine-induced sustained ventricular tachycardia in RyR2 R4496C+/− mice by increasing the threshold for triggered activity (P < 0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: